The Latest Cardiac and Vascular News
LAKE OSWEGO, Ore., March 14, 2019 /PRNewswire/ — BIOTRONIK today announced FDA approval of the Acticor and Rivacor high-voltage cardiac rhythm management (CRM) device families for treatment of patients with cardiac arrhythmias. The six new tachycardia solutions include Rivacor VR-T, Rivacor DR-T, […]
SAN DIEGO and BUELACH, Switzerland, Sept. 24, 2018 /PRNewswire/ — Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiroa and Xienceb drug-eluting stents (DES). The data shows statistically improved outcomes for patients treated with Orsiro across a range of clinical endpoints including 24-month target lesion […]
BOSTON–(BUSINESS WIRE)–InfoBionic, a digital health company focused on creating next-generation solutions for ambulatory, cardiac arrhythmia monitoring, today announced an exclusive, strategic agreement with medical device manufacturer BIOTRONIK for U.S. distribution of InfoBionic’s proprietary MoMe® Kardia system, effective immediately. “BIOTRONIK is a trusted […]
LAKE OSWEGO, Ore., Aug. 27, 2018 /PRNewswire/ — BIOTRONIK today announced that the company is now the exclusive US distributor for InfoBionic’s MoMe Kardia external cardiac diagnostic monitor. The device benefits patients suspected of experiencing cardiac arrhythmias. Patients experiencing cardiac arrhythmias face an increased […]
LAKE OSWEGO, Ore. and SILVER SPRING, Md., April 3, 2018 /PRNewswire/ — BIOTRONIK US and Aziyo today announced a strategic agreement allowing BIOTRONIK to distribute Aziyo’s CanGaroo® extracellular matrix (ECM) cardiovascular implantable electronic device (CIED) envelopes in the United States. BioEnvelope will be available from BIOTRONIK starting in April 2018. BioEnvelope […]
Denver, United States / Buelach, Switzerland, 31.10.2017 (PresseBox) – Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market. In addition, clinical and preclinical data presented about Magmaris2 reinforce the case that the […]
(PresseBox) – BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical performance of a new coronary stent in de novo coronary artery lesions. On September 28, first Dr. Marco Moccetti, Cardiocentro Ticino, Lugano, Switzerland, […]
Robustly Positive Results of SPAIN Study Published in Journal of American College of Cardiology BERLIN, Germany, October 4, 2017 – BIOTRONIK’s exclusive rate responsive technology, Closed Loop Stimulation (CLS) has shown to reduce fainting in pacemaker patients with vasovagal syncope […]
Landmark Data Published by The Lancet Demonstrates Statistically Significant Lower Event Rates with Orsiro BARCELONA, Spain, August 28, 2017 – BIOTRONIK today announced data from the BIOFLOW-V randomized trial comparing Orsiro1 and Xience2 drug-eluting stents (DES) with 12-month target lesion failure (TLF) […]
LAKE OSWEGO, Ore., Aug. 21, 2017 /PRNewswire/ — BIOTRONIK today announced FDA approval and commercial availability of Edora HF-T QP, an MR conditional quadripolar (QP) cardiac resynchronization therapy pacemaker (CRT-P) with MRI AutoDetect technology. With a volume of 15 cc, Edora HF-T QP is […]
